ID   A549-ACE2
AC   CVCL_C0Q5
SY   A549-Ace2
DR   cancercelllines; CVCL_C0Q5
DR   GEO; GSM5224710
DR   GEO; GSM5224711
DR   GEO; GSM5224712
DR   PRIDE; PXD019645
DR   PRIDE; PXD023418
DR   Wikidata; Q112927063
RX   PubMed=33208793;
CC   Group: SARS-CoV-2 research cell line.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 13557; ACE2.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=33208793; DOI=10.1038/s41467-020-19619-7;
RA   Klein S., Cortese M., Winter S.L., Wachsmuth-Melm M., Neufeldt C.J.,
RA   Cerikan B., Stanifer M.L., Boulant S., Bartenschlager R.F.W.,
RA   Chlanda P.;
RT   "SARS-CoV-2 structure and replication characterized by in situ
RT   cryo-electron tomography.";
RL   Nat. Commun. 11:5885.1-5885.10(2020).
//